Floatz logo

Risperdal

Negative Symptoms

National Institute of Mental Health and Neuro Sciences, IndiaPhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Negative Symptoms cohort.

Asset / SponsorPhaseRating
CITALOPRAM
National Institute of Mental Health and Neuro Sciences, India
Phase 4BB
Vortioxetine
Northwell Health
Phase 4BB
Guarana Extract
Faculdade de Medicina do ABC
Phase 2B
BRADANICLINE
Targacept Inc.
Phase 2B
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 2CCC

View all 11 →

Same molecule, other indications

Risperdal is also rated in:

major depressive disorderDormant
BBB
Indicative ·
78 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
77 / 100
View asset →
schizoaffective disorderDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →